Phase 2 Study of the Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Men Who Have Sex With Men (HPTN 069/ACTG A5305)

Maraviroc (MVC) is a candidate for human immunodeficiency virus (HIV) pre-exposure prophylaxis

Forecasting growth cycle turning points using US and Japanese professional forecasters

Contingency table, Growth cycle, Professional forecaster, Real-time data, Turning point, E32, E37,

Reduction of HIV Persistence Following Transplantation in HIV-Infected Kidney Transplant Recipients

Chronic inflammation may contribute to HIV persistence through a number of potential pathways. We explored the impact of immunosuppressant therapy on peripheral blood measures of HIV persistence following kidney transplantation. Stored plasma and peripheral blood mononuclear cells prior to transplantation and at weeks 12, 26, 52 and 104 post-transplant were obtained from 91 transplant recipients. In a multivariate model, higher pre-transplant plasma HIV RNA level (p<.0001) and a longer duration of follow-up post-transplant (p=0.09) were associated with higher post-transplant plasma HIV RNA levels. A higher baseline HIV DNA (p<.0001) was significantly associated with higher HIV DNA levels post-transplant, while higher CD4+ T cell count (p=0.001), sirolimus use (p=0.04) and a longer duration of follow-up (p=0.06) were associated with lower post-transplant HIV DNA levels. The association between sirolimus exposure and lower frequency of cells containing HIV DNA levels post-transplant suggest that the immune-modifying drugs may affect the level of HIV persistence during effect therapy. Future studies of sirolimus as a reservoir-modifying agent are warranted